These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31157088)

  • 1. Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.
    Fobelo Lozano MJ; Sánchez-Fidalgo S
    Eur J Hosp Pharm; 2019 Jan; 26(1):4-9. PubMed ID: 31157088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
    Curtis JR; Yun H; Matthews R; Saag KG; Delzell E
    Arthritis Care Res (Hoboken); 2012 Jul; 64(7):1054-60. PubMed ID: 22328117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab: A Unique Perspective on Adherence and Cost-effectiveness Compared With Oral Bisphosphonates in Osteoporosis Patients.
    Morizio P; Burkhart JI; Ozawa S
    Ann Pharmacother; 2018 Oct; 52(10):1031-1041. PubMed ID: 29616561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S; Glendenning P; Inderjeeth CA
    Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis.
    Ringe JD
    Patient Prefer Adherence; 2010 Jul; 4():231-45. PubMed ID: 20694183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable bisphosphonates for the treatment of osteoporosis.
    Reginster JY; Burlet N; Close P; Bruyere O
    Womens Health (Lond); 2007 Nov; 3(6):719-23. PubMed ID: 19803981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid infusion for prevention and treatment of osteoporosis.
    Sunyecz JA
    Int J Womens Health; 2010 Oct; 2():353-60. PubMed ID: 21151682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
    Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
    Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of postmenopausal osteoporosis, patient perspectives - focus on once yearly zoledronic acid.
    Carmona R; Adachi R
    Patient Prefer Adherence; 2009 Nov; 3():189-93. PubMed ID: 19936161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-related osteonecrosis of the jaw after once-a-year intravenous zoledronic acid infusion for osteoporosis: Report of eight cases.
    Favia G; Tempesta A; Limongelli L; Crincoli V; Maiorano E
    Quintessence Int; 2016; 47(5):433-40. PubMed ID: 26665262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.